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Introduction
Despite scientific advances in understanding the causes and treatment of human malignancies, the treatment of brain tumors, both primary and metastatic, remains a persistent challenge. Many chemotherapeutic agents that are potent and efficacious against peripheral tumors have been found to be ineffective in treating tumors in the brain. In general, the poor response of CNS tumors to chemotherapy drugs is multifactorial, but the inability to effectively deliver therapeutic agents to the CNS across the blood-brain-barrier (BBB) is certainly a well-known mechanism (Pardridge, 2001; Motl et al., 2006) . The BBB is a highly developed defense mechanism that separates the brain from the peripheral circulation, thereby protecting it from circulating toxins and potentially harmful chemicals. The barrier is formed by a dense network of brain capillaries where the endothelial cells contain tight junctions, limiting paracellular transport. In addition, the barrier function is further strengthened by the expression of active efflux transporters in the endothelium. These efflux pumps mediate the brain-to-blood efflux of substrate drugs and thus limit their CNS exposure (Pardridge, 1999; Allen and Smith, 2001; Golden and Pollack, 2003) .
Drug efflux pumps present at the BBB include ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp; MDR1/ABCB1), breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRP2/ABCC2, MRP4/ABCC4), as well as transporters of the solute carrier family such as organic anion-transporting polypeptide 1A2
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5 Despite high rates of response after whole-brain radiotherapy, rapid recurrence is common and long-term survival is rare (Norden et al., 2011) . The classic antifolate agent, methotrexate (MTX), is widely used for the treatment of primary CNS lymphoma and chemotherapy with methotrexate in combination with whole-brain radiotherapy has recently become the treatment of choice. A recent study has reported that high-dose methotrexate alone or in combination with other therapies is the most effective treatment available for PCNSL (Gerstner et al., 2008) .
Although efficacious, high-dose methotrexate therapy is associated with severe systemic and neurologic toxicities, with studies reporting complications leading to patient death in some cases.
Most of the systemic toxicities can be attributed to greater exposure of tissues following treatment with methotrexate at high doses, a need arising from the inability of methotrexate to penetrate the BBB. Preclinical studies have shown that brain distribution of methotrexate is severely restricted with only 5% of free drug in plasma crossing the BBB to reach the brain (Devineni et al., 1996; Dai et al., 2005) . In human, Blakeley and coworkers also reported a poor cerebral penetration of methotrexate (3.2% to 9.4%) in patients with recurrent high grade gliomas using microdialysis technique (Blakeley et al., 2009) . Pemetrexed (PMX, Alimta ® ) is a novel antifolate that was developed to overcome some of the problems associated with methotrexate therapy. It has been reported that it has potent anti-tumor activity against a variety of tumors including CNS malignancies (Kuo and Recht, 2006) . However, similar to methotrexate, distribution of pemetrexed across the BBB is also very limited (Dai et al., 2005) . The mechanisms behind the poor brain penetration of pemetrexed and methotrexate are poorly understood with one plausible explanation being the involvement of efflux transport systems at the BBB.
Brain Efflux Index (BEI) Method
The brain efflux study was performed using the intracerebral microinjection technique, as previously reported (Kakee et al., 1996) . and Bcrp1 (-/-) mice were anesthetized with an intraperitoneal dose of 100 mg/kg ketamine and 10 mg/kg xylazine (Boynton Health Service Pharmacy, Minneapolis, MN), and then mounted on a stereotaxic device. A borehole was made 3.8 mm lateral to the bregma and an injection needle was advanced to a depth of 2.5 mm from the surface of the scalp, i.e., into the secondary somatosensory cortex 10 mM D-glucose, and 10 mM HEPES, pH 7.4) was injected over 2 min using a 2.5-µL microsyringe (Hamilton, Reno, NE) fitted with a fine needle (32 gauge, Hamilton, Reno, NE).
The injection process was controlled by a Quintessential ® stereotaxic injector (Stoelting Co., IL, USA). Time zero was defined as the time when the injection was completed. After injection, the needle was left in place for additional 4 minutes to minimize the backflow of injected solution along the injection track. At designated time points post injection, mice were euthanized and decapitated. The right (ipsilateral), left (contralateral) cerebrum and cerebellum were harvested, weighed and homogenized in 3 volumes of 5% bovine serum albumin solution. A 100-µL sample of brain homogenate from the right, left cerebrum and cerebellum was mixed with 4 ml of scintillation fluid (ScintiSafe Econo cocktail; Thermo Fisher Scientific, Waltham, MA) and the associated radioactivity was measured in a liquid scintillation counter (LS-6500 instrument; 
The apparent BBB efflux rate constant, k eff , was obtained from the slope of the semilogarithmic plot of the value of (100-BEI) versus time using the linear regression function in SigmaPlot (version 9.0.1, SYSTAT software).
Determination of Brain Volume of Distribution by the Brain Slice Uptake Method
This article has not been copyedited and formatted. The final version may differ from this version. The volume of distribution of pemetrexed and methotrexate in the brain was determined by the in vitro brain slice uptake technique. Brain slices were prepared according to the method reported by Kakee et al. (Kakee et al., 1996) . In brief, coronal brain slices of the cortex (400 μ m)
were prepared using a Vibratome TM (series 1000, The Vibratome Company, Bannockburn, IL).
The slices were preincubated at 37˚C for 5 minutes in ECF buffer oxygenated with 95% O 2 and 5% CO 2. After preincubation, the slices were transferred into 5 ml oxygenated ECF buffer 
Steady-State Brain Distribution of Pemetrexed
In addition to the BEI study, steady-state brain distribution of pemetrexed was examined in wildtype and Bcrp1(-/-) mice. Alzet ® osmotic minipumps (Durect Corporation, Cupertino, CA) were used to continuously infuse drug into the peritoneal cavity for 72 hours. The pump operated at a flow rate of 1 µL/hr, resulting in a constant rate infusion of 25 mg/kg/day. Wild-type mice (n=5) This article has not been copyedited and formatted. The final version may differ from this version. and Bcrp1(-/-) mice (n=5) were anesthetized with an intraperitonal dose of 100 mg/kg ketamine and 10 mg/kg xylazine (Boynton Health Service Pharmacy, Minneapolis, MN). A small midline incision was made in the abdominal wall and the pumps were surgically implanted into the peritoneal cavity. The animals were allowed to recover on a heated pad and were administered ibuprofen in their drinking water for pain relief. The animals were euthanized after 72 hours by using a CO2 chamber. Blood was immediately harvested via cardiac puncture and collected in tubes preloaded with potassium EDTA (BD, Franklin Lakes, NJ). Whole brain was immediately harvested, rinsed with ice-cold saline to remove extraneous blood and flash frozen using liquid nitrogen. Plasma was isolated from blood by centrifugation at 3000 rpm for 10 min at 4°C. All samples were stored at -80°C until further analysis.
Quantification of Pemetrexed by Liquid Chromatography-Mass Spectometry (LC-MS/MS)
Mouse plasma and brain samples were analyzed by a rapid and sensitive LC-MS/MS. Whole brain samples were first homogenized in solution comprised of water and ethanol (20:80) with a volume ratio of 1:3. Acetonitrile containing the internal standard (20 ng/mL) was then added to the plasma or brain homogenate, followed by centrifugation to remove precipitated proteins.
The supernatant was diluted with two volumes of water and chromatographed under reversephase conditions on a Betasil C18 analytical column ( spectrometry using the parent ion mass-to-charge ratio of 428.1 and the daughter ion m/z of 281.1. The lower limit of quantification was 1 ng/mL.
Statistical analysis
Statistical analysis was conducted using SigmaStat (version 3.1, SYSTAT software). Statistical comparisons between two groups were made by using two-sample t-test at p < 0.05 significance level. Multiple groups were compared by one-way analysis of variance with the Holm-Sidak post hoc test for multiple comparisons at a significance level of p < 0.05.
Results
BEI method to characterize the brain-to-blood transport of pemetrexed and methotrexate
The brain efflux index (BEI) method, also referred to as the intracerebral microinjection technique, is a novel technique to study mechanisms of brain-to-blood efflux transport at the BBB (Kakee et al., 1996; Kusuhara et al., 2003) . Because it isolates efflux processes directly, rather than considering efflux as modulator of brain distribution, BEI is an excellent method for determining efflux clearance and studying the mechanisms behind active transport of compounds from the brain. This in vivo method has been extensively used to study the brain efflux clearance of various compounds, including steroid conjugates, valproic acid, nucleoside analogs, buprenorphine, human amyloid-β peptide, benzylpenicillin and quinidine (Kusuhara et al., 1997; Takasawa et al., 1997; Sugiyama et al., 2001; Kakee et al., 2002; Ohtsuki et al., 2002; Kikuchi et al., 2003; Ito et al., 2006; Suzuki et al., 2007) . In the present study, we first validated the technique by studying brain efflux index of valproic acid. The brain elimination half-life of valproic acid was determined to be 2 minutes (range: 1.6 -2.3 minutes, N=3), a value that is consistent with the reported value of 3.7 minutes from previous studies using the same technique This article has not been copyedited and formatted. The final version may differ from this version. 
Pemetrexed and Methotrexate Elimination from Mouse Brain
The efflux of methotrexate and pemetrexed from mouse brain was investigated using the BEI method. Figure 1A shows the time profile of the percentage of (Figure 4) .
Role of Mrp2 in Transport of
Role of Organic Anion Transporters in Elimination of Pemetrexed and Methotrexate From Mouse Brain
Probenecid is a non-specific inhibitor of organic anion transporters, including MRPs, organic anion transporters (Oats) and organic anion transporting polypeptides (Oatps) (Bakos et al., 2000; Sugiyama et al., 2001; Haimeur et al., 2004) . In the present study, the involvement of organic anion transporters in brain-to-blood transport of the two antifolates was determined by examining the inhibitory effect of probenecid (Figure 6 ). In wild-type mice, simultaneous injection of probenecid (100 mM in the injectate) significantly increased the fraction of [ Benzylpenicillin is a selective Oat3 substrate/inhibitor (Kikuchi et al., 2003) . In the present study, the possible role of Oat3 in the efflux transport of the antifolates was examined via the inhibitory effect of benzylpenicillin. As shown in Figure 6 , the elimination of both [ Table 1 and Table 2 , respectively.
Distribution Volume of Pemetrexed and Methotrexate in Mouse Brain
The distribution volume of pemetrexed and methotrexate in mouse brain was determined by in vitro brain slice uptake technique. Table 3) .
Discussion
The potential use of pemetrexed in treatment of primary and secondary brain tumors has gained more interest in recent years. Methotrexate, a classical antifolate widely used for brain metastasis, has restricted brain penetration which necessitates a high systemic dose to achieve a therapeutic effect. In spite of the tremendous need to enhance the brain penetration of these antifolate agents, the mechanisms behind limited brain distribution are still not clear. In the present study, we characterized the brain elimination kinetics of pemetrexed and methotrexate, and explored the involvement of several efflux transporters in the brain distribution of the two agents.
This article has not been copyedited and formatted. The final version may differ from this version. Using the BEI method, we show that both pemetrexed and methotrexate are rapidly eliminated from the brain with their half-lives in the brain being 0.65 hrs and 0.48 hrs, respectively. The short retention time in the brain may be attributed to very limited brain distribution volume.
Specifically, the distribution volume (V d ) of pemetrexed and methotrexate in mouse brain, as determined by brain slide uptake method, is close to brain interstitial fluid space of 0.8 mL/g brain (Reinoso et al., 1997) . On the other hand, efficient efflux transport may also play a role in quickly clearing these antifolate agents from the brain. In the present study, we first confirmed the involvement of active efflux transport in the brain elimination of pemetrexed. The elimination of [ 3 H]-PMX from the brain was almost completely inhibited in presence of 50 mM unlabelled PMX, suggesting that the contribution of passive diffusion to PMX brain efflux transport is very limited and active transport accounts for the majority of the total efflux. This is consistent with physicochemical properties of pemetrexed. As an anionic compound with a log P of -1.5, it is unlikely that pemetrexed can cross biological membranes readily by passive diffusion. As a matter of fact, intracellular transport of pemetrexed is also facilitated by influx transporters, including reduced folate carrier (RFC), folate receptor (FR) and proton-coupled folate transporter (PCFT). Therefore it is plausible that active drug transporters are required to remove pemetrexed across lipid membranes, and across the BBB out of the brain.
After confirming the involvement of active efflux transport in the brain distribution of pemetrexed, we then explored the potential roles of several efflux transporters at the BBB in eliminating pemetrexed and methotrexate from the brain. The first transporter we investigated is Mrp2. In a recent study, Vlaming et al. have reported that Mrp2 plays an important role in determining the total body clearance of methotrexate (Vlaming et al., 2009) 
. Other in vitro
This article has not been copyedited and formatted. The final version may differ from this version. (Pratt et al., 2002; El-Sheikh et al., 2007) . Given the purported expression of Mrp2 at the BBB, we tested the hypothesis that Mrp2 may transport pemetrexed and methotrexate at the BBB and thus limit the brain penetration of the antifolates. However, contrary to the reported in vitro findings, we did not observe any influence of Mrp2 on the efflux of either pemetrexed or methotrexate from the brain. Although the functional relevance of Mrp2 in the systemic disposition of its substrates has been established via studies using Mrp2 gene knockout mice (Vlaming et al., 2006; Tian et al., 2007; Ieiri et al., 2009; Vlaming et al., 2009) , the role of MRP2 in brain distribution of drugs is poorly understood. Our findings further confirm this and advocates for the need of further research to investigate the role of Mrp2 at the BBB that include additional expression studies.
In contrast to MRP2, the role of BCRP as a gate keeper at the BBB has been well established.
More importantly, BCRP also mediates the cellular transport of pemetrexed and methotrexate as indicated by in vitro studies (Volk and Schneider, 2003; Li et al., 2011) . The current BEI study revealed that Bcrp plays a significant role in the brain elimination of methotrexate, but not pemetrexed. This is not totally unexpected, because even though pemetrexed is a structurally similar antifolate, it may possess different physiochemical properties that affect the binding affinities for the transporters. Based on the available in vitro data using in vitro vesicular uptake method, Bcrp-mediated intrinsic clearance (V max /K m ) of methotrexate is about 3-fold higher than that of pemetrexed (manuscript submitted). Therefore, the discrepancy in Bcrp-mediated efflux of the two antifolates may be explained by their different affinities for this transporter.
This article has not been copyedited and formatted. The final version may differ from this version. (Kusuhara et al., 1999; Kikuchi et al., 2003; Mori et al., 2003) . It mediates the brain-to-blood transport of many hydrophilic organic anions; including indoxyl sulfate (IS), 6-mercaptopurine (6-MP), paminohippuric acid (PAH), benzylpenicillin (PCG) and homovanillic acid (HVA) (Ohtsuki et al., 2002; Kikuchi et al., 2003; Mori et al., 2004; Kusuhara and Sugiyama, 2005) . Due to the cellular localization of Oat3, it is believed that Oat3 can only transport its substrate from brain extracellular space to brain capillary endothelial cells (Kusuhara and Sugiyama, 2005) ; and another transporter is needed to remove the molecules from the endothelial cells into the bloodstream. The ABC transporter MRP4 has been shown to transport both pemetrexed and methotrexate. Specifically, MRP4 mediates the transport of methotrexate with K m of 220 µM and the expression of MRP4 correlates with the in vitro chemosensitivity of tumor cells to pemetrexed Hanauske et al., 2007) . Given the functional role of Mrp4 at BBB (Leggas et al., 2004; Belinsky et al., 2007) , Mrp4 is likely to function at the luminal membrane cooperatively with Oat3 for the brain-to-blood transport of pemetrexed and methotrexate. In summary, the present study examined the role of several active efflux transporters at the BBB in the brain distribution of pemetrexed and methotrexate. The results of this study show that both methotrexate and pemetrexed undergo saturable efflux from brain. Of the two transporters investigated in this study using gene knockout mice, Mrp2 does not play a role in the brain clearance of the two antifolates, whereas Bcrp makes a significant contribution This article has not been copyedited and formatted. The final version may differ from this version. to the brain elimination of methotrexate, but not pemetrexed. In addition, the brain-to-blood transport of both agents was sensitive to probenecid and benzylpenicillin, suggesting the involvement of organic anion transporters, with Oat3 being a possibility.
In conclusion, an important mechanism behind the low brain distribution of these antifolates is active efflux transport by multiple efflux systems working in tandem at the BBB. This study isolates several efflux systems that could be involved in the efflux of the two antifolates at the BBB.
This article has not been copyedited and formatted. The final version may differ from this version. (Dai et al., 2005) b) (Devineni et al., 1996) 
